A 42-year-old woman from Delhi presents with a 6-month history of symmetrical pain and swelling in the small joints of both hands, wrists, and feet. She reports morning stiffness lasting 2 hours. On examination, she has soft tissue swelling over the PIP and MCP joints bilaterally, with positive squeeze test. Laboratory investigations show: ESR 68 mm/hr, CRP 12 mg/dL, RF 1:320, anti-CCP antibodies positive. X-ray of hands shows juxta-articular osteopenia and early marginal erosions. She has no extra-articular manifestations. Which of the following is the most appropriate next step in management?

Explanation

## Clinical Assessment **Key Point:** This patient has established, seropositive, erosive rheumatoid arthritis (RA) with poor prognostic features (high RF, positive anti-CCP, early erosions, elevated inflammatory markers). The 6-month disease duration places her within the critical window for DMARD initiation. ## Rationale for Correct Answer **High-Yield:** Methotrexate monotherapy is the gold-standard first-line DMARD for RA, especially in seropositive disease with erosive changes. Early and aggressive DMARD therapy within 3 months of symptom onset is associated with better long-term outcomes and remission rates [cite:Harrison 21e Ch 312]. **Clinical Pearl:** The presence of erosions on imaging indicates structural damage and is a strong indication for immediate DMARD initiation. Folic acid (1 mg daily) is mandatory to reduce methotrexate toxicity. ## Why Methotrexate is First-Line 1. Proven efficacy in halting radiological progression 2. Cost-effective and well-tolerated in most patients 3. Can be combined with biologics if inadequate response 4. Allows assessment of response before escalation ## Management Algorithm ```mermaid flowchart TD A[Established RA with erosions]:::outcome --> B[Start DMARD within 3 months]:::action B --> C[Methotrexate 15-25 mg weekly]:::action C --> D{Response at 12 weeks?}:::decision D -->|Yes - remission/LDA| E[Continue MTX, monitor]:::action D -->|No - inadequate| F[Add biologic TNF-i or switch]:::action E --> G[Target: DAS28 remission]:::outcome F --> H[Combination therapy or escalation]:::action ``` **Mnemonic:** **DMARD START** — Disease-Modifying Anti-Rheumatic Drug; Start early, Target remission, Assess response, Review at 12 weeks, Titrate or add biologics. ## Monitoring Requirements - Baseline: CBC, LFTs, renal function - Monthly for first 3 months, then 3-monthly - Target: DAS28 <2.6 (remission) or <3.2 (low disease activity) - NSAIDs and low-dose prednisolone (<7.5 mg/day) can be used as bridge therapy during DMARD ramp-up